**Supplemental Table 5. Number of Eyes Using Medical Therapy and Reduction of Medical Therapy from Baseline**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Visit** | **On Medical Therapy**  **[n/N (%)]** | | **Number of IOP-lowering Medications**  **[Mean ± (SD)**]  **[Range]** | | **Reduction in Number of IOP-lowering Medications from Baseline**  **[Mean ± (SD)**]  **[Range]**  **[*P*, paired *t* test]** | |
| **SGDD** | **CPC** | **SGDD** | **CPC** | **SGDD** | **CPC** |
| Baseline | 21/22  (95%) | 20/20  (100%) | 3.0 (±1.0)  [0 – 4] | 3.3 (±1.1)  [1 – 5] | - | - |
| Week 1 | 19/22 (86%) | 18/19 (95%) | 1.7\* (±1.6)  [0 – 4] | 2.8\* (±1.5)  [0 – 4] | 1.4\* (±1.2)  [0 – 4]  **[*P*<0.001]** | 0.4\* (±1.3)  [0 – 4]  [*P*=0.18] |
| Month 1 | 19/22 (86%) | 17/18 (94%) | 1.6 (±1.4)  [0 – 4] | 2.2 (±1.3)  [0 – 4] | 1.5 (±1.3)  [0 – 4]  **[*P*<0.001]** | 0.9 (±1.2)  [-1 – 3]  **[*P*=0.004]** |
| Month 3 | 18/21 (86%) | 15/18 (83%) | 1.4 (±1.4)  [0 – 4] | 2.1 (±1.4)  [0 – 4] | 1.7\* (±1.4)  [-1 – 4]  **[*P*<0.001]** | 1.1\* (±1.3)  [-1 – 4]  **[*P*=0.004]** |
| Month 6 | 17/19 (89%) | 18/19 (95%) | 1.9 (±1.3)  [0 – 4] | 2.2 (±1.2)  [0 – 4] | 1.1 (±1.1)  [-1 – 3]  **[*P*=0.001]** | 1.1 (±1.0)  [-1 – 3]  **[*P*<0.001]** |
| Month 12 | 14/16 (88%) | 15/16 (94%) | 2.1 (±1.3)  [0 – 4] | 1.7 (±1.4)  [0 – 4] | 0.8 (±0.7)  [0 – 2]  **[*P*=0.001]** | 1.5 (±1.3)  [0 – 4]  **[*P*<0.001]** |
| Year 2 | 4/6 (67%) | 8/9  (89%) | 1.5 (±1.6)  [0 – 3] | 1.4 (±1.0)  [0 – 3] | 1.2 (±1.2)  [0 – 3]  [*P*=0.06] | 2.0 (±1.4)  [0 – 4]  **[*P*=0.003]** |
| Year 3 | 5/6 (83%) | 5/5 (100%) | 2.2 (±1.7)  [0 – 4] | 2.2 (±0.8)  [1 – 3] | 0.8 (±1.2)  [0 – 3]  [*P*=0.14] | 1.6 (±0.9)  [1 – 3]  [*P*=0.02] |

Abbreviations: SGDD=second glaucoma drainage device; CPC=cyclophotocoagulation; IOP=intraocular pressure; SD=standard deviation

*P* obtained from paired t test for within each group

\* for *P* < 0.05, \*\* for *P* < 0.01, and \*\*\* for *P* < 0.001 obtained from two sample *t* test for comparing between groups